Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 6.

Journal Article

Abboud, Tammam ORCID: 0000-0003-4379-6961, Melich, Patrick, Scheithauer, Simone, Rohde, Veit and Schatlo, Bawarjan ORCID: 0000-0002-9221-0843 (2023). Complications, Length of Hospital Stay, and Cost of Care after Surgery for Pyogenic Spondylodiscitis. J. Neurol. Surg. Part A, 84 (1). S. 52 - 58. NEW YORK: THIEME MEDICAL PUBL INC. ISSN 2193-6323

Bettag, Christoph, Abboud, Tammam, von der Brelie, Christian, Melich, Patrick, Rohde, Veit and Schatlo, Bawarjan (2020). Do we underdiagnose osteoporosis in patients with pyogenic spondylodiscitis? Neurosurg. Focus, 49 (2). ROLLING MEADOWS: AMER ASSOC NEUROLOGICAL SURGEONS. ISSN 1092-0684

Herrlinger, Ulrich, Schaefer, Niklas, Steinbach, Joachim P., Weyerbrock, Astrid ORCID: 0000-0001-9060-4462, Hau, Peter ORCID: 0000-0003-3894-5053, Goldbrunner, Roland, Friedrich, Franziska, Rohde, Veit, Ringel, Florian, Schlegel, Uwe, Sabel, Michael, Ronellenfitsch, Michael W., Uhl, Martin, Maciaczyk, Jaroslaw, Grau, Stefan, Schnell, Oliver, Haenel, Mathias, Krex, Dietmar, Vajkoczy, Peter, Gerlach, Ruediger, Kortmann, Rolf-Dieter, Mehdorn, Maximilian, Tuettenberg, Jochen, Mayer-Steinacker, Regine, Fietkau, Rainer, Brehmer, Stefanie, Mack, Frederic, Stuplich, Moritz, Kebir, Sied, Kohnen, Ralf, Dunkl, Elmar, Leutgeb, Barbara, Proescholdt, Martin, Pietsch, Torsten, Urbach, Horst, Belka, Claus, Stummer, Walter and Glas, Martin (2016). Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O-6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. J. Clin. Oncol., 34 (14). S. 1611 - 1623. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Herrlinger, Ulrich, Schaefer, Nildas, Steinbach, Joachim Peter, Weyerbrock, Astrid, Hau, Peter, Goldbrunner, Roland, Friedrich, Franziska, Rohde, Veit, Ringel, Florian, Braun, Christian, Kohnen, Ralf, Leutgeb, Barbara, Belka, Claus, Urbach, Horst, Stummer, Walter and Gies, Martin (2014). Survival and quality of life in the randomized, multicenter GLARIUS trial investigating bevacizumab/irinotecan versus standard temozolornide in newly diagnosed, MGMT-non-methylated glioblastoma patients. J. Clin. Oncol., 32 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Kebir, Sied, Schaub, Christina, Junold, Nina, Hattingen, Elke ORCID: 0000-0002-8392-9004, Schaefer, Niklas, Steinbach, Joachim P., Weyerbrock, Astrid ORCID: 0000-0001-9060-4462, Hau, Peter, Goldbrunner, Roland, Galldiks, Norbert ORCID: 0000-0002-2485-1796, Weller, Johannes ORCID: 0000-0001-5818-5392, Mack, Frederic, Tzaridis, Theophilos ORCID: 0000-0001-9651-1144, Baehr, Oliver, Seidel, Clemens, Schlegel, Uwe, Schmidt-Graf, Friederike, Rohde, Veit, Borchers, Christian, Tabatabai, Ghazaleh ORCID: 0000-0002-3542-8782, Haenel, Mathias, Sabel, Michael, Gerlach, Ruediger, Krex, Dietmar, Belka, Claus, Vatter, Hartmut, Proescholdt, Martin, Glas, Martin and Herrlinger, Ulrich (2019). Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial. J. Neuro-Oncol., 144 (3). S. 501 - 510. NEW YORK: SPRINGER. ISSN 1573-7373

Schaub, Christina, Kebir, Sied, Junold, Nina, Hattingen, Elke ORCID: 0000-0002-8392-9004, Schaefer, Niklas, Steinbach, Joachim P., Weyerbrock, Astrid ORCID: 0000-0001-9060-4462, Hau, Peter ORCID: 0000-0003-3894-5053, Goldbrunner, Roland, Niessen, Michael, Mack, Frederic, Stuplich, Moritz, Tzaridis, Theophilos, Baehr, Oliver, Kortmann, Rolf-Dieter, Schlegel, Uwe, Schmidt-Graf, Friederike, Rohde, Veit, Braun, Christian, Haenel, Mathias, Sabel, Michael, Gerlach, Ruediger, Krex, Dietmar, Belka, Claus, Vatter, Hartmut, Proescholdt, Martin, Herrlinger, Ulrich and Glas, Martin (2018). Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial. J. Cancer Res. Clin. Oncol., 144 (8). S. 1581 - 1590. NEW YORK: SPRINGER. ISSN 1432-1335

This list was generated on Sat Apr 20 07:29:10 2024 CEST.